title: Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?
authors.affiliation: Institute for Epidemiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
authors.forename: Roland
authors.initials: R
authors.lastname: Diel
authors.forename: Robert
authors.initials: R
authors.lastname: Loddenkemper
authors.forename: Giovanni
authors.initials: G
authors.lastname: Sotgiu
authors.forename: G B
authors.initials: GB
authors.lastname: Migliori
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000191:economics*; D016527:Drug Costs; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000191:economics*; D055985:Latent Tuberculosis / Q000188:drug therapy* / Q000191:economics*; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin; C018421:rifapentine